Cytosorbents (NASDAQ:CTSO) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO) in a research note issued to investors on Thursday. The firm issued a hold rating on the medical research company’s stock.

Separately, D. Boral Capital reiterated a “buy” rating and issued a $10.00 price target on shares of Cytosorbents in a research note on Tuesday, April 1st. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $4.67.

Cytosorbents Stock Down 2.0 %

Cytosorbents stock opened at $0.97 on Thursday. Cytosorbents has a twelve month low of $0.70 and a twelve month high of $1.61. The stock has a market cap of $53.04 million, a P/E ratio of -2.69 and a beta of 0.78. The company’s 50-day moving average price is $1.07 and its two-hundred day moving average price is $1.04. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06.

Cytosorbents (NASDAQ:CTSO) last released its quarterly earnings results on Monday, March 31st. The medical research company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.04. Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%. The business had revenue of $9.20 million during the quarter, compared to the consensus estimate of $10.09 million. As a group, analysts expect that Cytosorbents will post -0.3 EPS for the current year.

Hedge Funds Weigh In On Cytosorbents

Hedge funds and other institutional investors have recently made changes to their positions in the company. Avenir Corp increased its stake in Cytosorbents by 4.0% in the fourth quarter. Avenir Corp now owns 3,093,946 shares of the medical research company’s stock valued at $2,815,000 after acquiring an additional 118,387 shares during the last quarter. Skylands Capital LLC increased its stake in shares of Cytosorbents by 1.0% in the 4th quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock valued at $2,531,000 after purchasing an additional 26,195 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after buying an additional 32,415 shares in the last quarter. Raymond James Financial Inc. bought a new position in Cytosorbents in the fourth quarter valued at about $99,000. Finally, Northern Trust Corp grew its position in Cytosorbents by 22.3% in the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock valued at $83,000 after acquiring an additional 16,701 shares during the last quarter. 32.87% of the stock is currently owned by institutional investors and hedge funds.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.